Differential roles of uPAR in peritoneal ovarian carcinomatosis

Neoplasia

Volumn 14, Issue 4, 2012, Pages 259-270

  Al Hassan, Nada N ^a   Behzadian, Ali ^b   Caldwell, Ruth ^b   Ivanova, Vessela S ^c   Syed, Viqar ^c   Motamed, Kouros ^d   Said, Neveen A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Biomiga Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; PROTEIN ZO1; UROKINASE RECEPTOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; BLOOD VESSEL PERMEABILITY; CANCER SURVIVAL; CELL ADHESION; CELL INFILTRATION; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MESOTHELIUM CELL; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOMICROSCOPY; STROMA CELL; TISSUE MICROARRAY; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84860611297     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12442     Document Type: Article

References (58)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Lengyel E (2010). Ovarian cancer development and metastasis. Am J Pathol 177, 1053-1064.
3. Kenny HA, Nieman KM, Mitra AK, and Lengyel E (2011). The first line of abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov 1, 100-102.
4. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince T, and Brugge JS (2011). Ovarian cancer spheroids use myosingenerated force to clear the mesothelium. Cancer Discov 1, 144-157.
5. Vassalli JD, Baccino D, and Belin D (1985). A cellular binding site for the M r 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100, 86-92.
6. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, and Lengyel E (2011). Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 17, 459-471.
7. Mazar AP (2008). Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 14, 5649-5655.
8. Zhang J, Sud S, Mizutani K, Gyetko MR, and Pienta KJ (2011). Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 13, 23-30.
9. Jo M, Thomas KS, Takimoto S, Gaultier A, Hsieh EH, Lester RD, and Gonias SL (2007). Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 26, 2585-2594.
10. Lester RD, Jo M, Montel V, Takimoto S, and Gonias SL (2007). uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 178, 425-436.
11. Choong PF and Nadesapillai AP (2003). Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res (415 suppl), S46-S58.
12. Kohn EC, Travers LA, Kassis J, Broome U, and Klominek J (2005). Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn Cytopathol 33, 300-308.
13. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, and Annunziata CM (2010). Activation of NF-κB signaling by inhibitor of NF-κB kinase β increases aggressiveness of ovarian cancer. Cancer Res 70, 4005-4014.
14. Said NA, Elmarakby AA, Imig JD, Fulton DJ, and Motamed K (2008). SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia 10, 1092-1104.
15. Saito Y, Sekine W, Sano R, Komatsu S, Mizuno H, Katabami K, Shimada K, Oku T, and Tsuji T (2010). Potentiation of cell invasion and matrix metalloproteinase production by α3β1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clin Exp Metastasis 27, 197-205.
16. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, and Vassalli JD (1990). The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111, 783-792.
17. Gyetko MR, Todd RF, Wilkinson CC, and Sitrin RG (1994). The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93, 1380-1387.
18. Busso N, Masur SK, Lazega D, Waxman S, and Ossowski L (1994). Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126, 259-270.
19. Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, Schutz GJ, Freissmuth M, and Breuss JM (2012). VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 94, 125-135.
20. Balsara RD, Merryman R, Virjee F, Northway C, Castellino FJ, and Ploplis VA (2011). A deficiency of uPAR alters endothelial angiogenic function and cell morphology. Vasc Cell 3, 10.
21. Prager GW, Breuss JM, Steurer S, Mihaly J, and Binder BR (2004). Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 103, 955-962.
22. Malla RR, Gopinath S, Gondi CS, Alapati K, Dinh DH, Gujrati M, and Rao JS (2011). Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 18, 419-434.
23. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, and Caldwell RB (2003). VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 17, 752-754.
24. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, and Caldwell RB (2003). Experimental diabetes causes breakdown of the bloodretina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162, 1995-2004.
25. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, and Coukos G (2002). Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 161, 2295-2309.
26. Said N and Motamed K (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167, 1739-1752.
27. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, and Motamed K (2007). Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5, 1015-1030.
28. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Rømer J, Solberg H, Ellis V, Danø K, and Degen JL (1995). The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270, 16886-16894.
29. Said N, Najwer I, and Motamed K (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factordependent survival signaling in ovarian cancer. Am J Pathol 170, 1054-1063.
30. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, and Motamed K (2007). SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9, 23-35.
31. Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K, and Theodorescu D (2009). The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 28, 3487-3498.
32. Said N, Smith S, Sanchez-Carbayo M, and Theodorescu D (2011). Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 121, 132-147.
33. Coyne CB, Ribeiro CM, Boucher RC, and Johnson LG (2003). Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J Pharmacol Exp Ther 305, 440-450.
34. Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, and Johnson LG (2002). Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 13, 3218-3234.
35. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Trope CG, Bryne M, Risberg B, van de Putte G, et al. (2002). Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are downregulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 19, 135-144.
36. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo K-T, Yeo T-K, Sioussat TM, and Dvorak HF (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55, 360-368.
37. Hu L, Ferrara N, and Jaffe RB (2006). Paracrine VEGF/VE-cadherin action on ovarian cancer permeability. Exp Biol Med 231, 1646-1652.
38. Yang J, Duh EJ, Caldwell RB, and Behzadian MA (2010). Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/β-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci 51, 3273-3280.
39. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, et al. (2007). Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophagelike cells. Blood 110, 4319-4330.
40. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, and Balkwill FR (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176, 5023-5032.
41. Fang J, Wei WN, Xia LH, and Song SJ (2004). Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 25, 143-146.
42. Nalla AK, Gogineni VR, Gupta R, Dinh DH, and Rao JS (2011). Suppression of uPA and uPAR blocks radiation-induced MCP-1 mediated recruitment of endothelial cells in meningioma. Cell Signal 23, 1299-1310.
43. Raghu H, Nalla AK, Gondi CS, Gujrati M, Dinh DH, and Rao JS (2012). uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells. Mol Oncol 6, 33-47.
44. Chechlinska M, Kaminska J, Markowska J, Kramar A, and Steffen J (2007). Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers 22, 172-180.
45. Chen SS, Michael A, and Butler-Manuel SA (2012). Advances in the treatment of ovarian cancer-a potential role of antiinflammatory phytochemicals. Discov Med 13, 7-17.
46. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17, 6083-6096.
47. Giuntoli RL II, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, and Oelke M (2009). Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29, 2875-2884.
48. Akutagawa N, Nishikawa A, Iwasaki M, Fujimoto T, Teramoto M, Kitajima Y, Endo T, Shibuya M, and Kudo R (2002). Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res 93, 644-651.
49. Brown CM, Mulcahey TA, Filipek NC, and Wise PM (2010). Production of proinflammatory cytokines and chemokines during neuroinflammation: novel roles for estrogen receptors α and β. Endocrinology 151, 4916-4925.
50. Funatsu H, Noma H, Mimura T, Eguchi S, and Hori S (2009). Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116, 73-79.
51. Ahmed N, Riley C, Oliva K, Rice G, and Quinn M (2005). Ascites induces modulation of α6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 92, 1475-1485.
52. Kobayashi H, Yagyu T, Kondo T, Kurita N, Inagaki K, Haruta S, Kawaguchi R, Kitanaka T, Sakamoto Y, Yamada Y, et al. (2005). Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor κB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res 65, 10464-10471.
53. Mekkawy AH, De Bock CE, Lin Z, Morris DL, Wang Y, and Pourgholami MH (2010). Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun 399, 738-743.
54. Mekkawy AH, Morris DL, and Pourgholami MH (2012). HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol 2012, 950749.
55. Begum FD, Hogdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Hoyer-Hansen G, Ring-Larsen H, and Hogdall EV (2004). The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res 24, 1981-1985.
56. Chambers SK, Gertz RE Jr, Ivins CM, and Kacinski BM (1995). The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75, 1627-1633.
57. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, and Sidenius N (2004). Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 91, 403-411.
58. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, et al. (1998). The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58, 1843-1849.